Achalasia—An Autoimmune Inflammatory Disease: A Cross-Sectional Study

Table 3

Percentage of Th22-, Th17-, Th2-, Th1-, and Tregs-circulating cells in achalasia patients.

	Healthy donors	Type I achalasia	Type II achalasia	Type III achalasia
	(n = 20)	(n = 6)	(n = 8)	(n = 5)
IL-22-expressing T cells; (Th22 %)
CD3^+/CD4^+/CD161^−/IL-22^+
Mean ± SEM	1.3 ± 0.1	6.4 ± 0.7	5.9 ± 0.9	11.4 ± 0.7
Median	1.4	6.1	5.7	11.3
Range	0.4–2.7	5.1–8.9	3.3–9.4	9.5–13.8
IL-17A-expressing T cells; (Th17 %)
CD3^+/CD4^+/CD161^+/IL-17A^+
Mean ± SEM	1.6 ± 0.1	4.2 ± 0.1	6.2 ± 0.6	9.4 ± 0.6
Median	1.7	4.1	6.4	10.0
Range	0.6–2.7	3.8–6.7	4.0–8.2	7.2–10.6
IL-4-expressing T cells; (Th2 %)
CD3^+/CD4^+/CD14^−/IL-4^+
Mean ± SEM	1.6 ± 0.2	2.3 ± 1.1	5.0 ± 0.5	3.6 ± 0.5
Median	1.6	2.5	4.7	4.2
Range	0.2–2.6	1.5–7.83	3.8–7.2	2.0–4.6
IFN-γ-expressing T cells; (Th1 %)
CD3^+/CD4^+/CD14^−/IFN-
Mean ± SEM	1.7 ± 0.1	2.8 ± 0.5	3.4 ± 0.3	3.4 ± 0.5
Median	1.7	2.6	3.2	3.7
Range	0.7–3.0	1.8–4.2	2.7–4.6	2.1–4.7
Foxp3-expressing T cells; (Tregs %)
CD3^+/CD4^+/CD25^hi/Foxp3^+
Mean ± SEM	5.2 ± 0.4	4.3 ± 0.6	5.9 ± 0.6	10.7 ± 0.9
Median	4.6	4.2	6.1	10.8
Range	2.3–7.3	2.5–6.2	3.7–7.2	7.7–12.8

control versus achalasia patients.
control versus achalasia patients.
control versus achalasia patients.